CO6190508A2 - Composiciones farmaceuticas de inhibidores de la hdac y compuestos metalicos quelables y complejos quelados metalicos inhibidores de la hdac - Google Patents

Composiciones farmaceuticas de inhibidores de la hdac y compuestos metalicos quelables y complejos quelados metalicos inhibidores de la hdac

Info

Publication number
CO6190508A2
CO6190508A2 CO09041802A CO09041802A CO6190508A2 CO 6190508 A2 CO6190508 A2 CO 6190508A2 CO 09041802 A CO09041802 A CO 09041802A CO 09041802 A CO09041802 A CO 09041802A CO 6190508 A2 CO6190508 A2 CO 6190508A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
chelated
saha
hdac
iron
Prior art date
Application number
CO09041802A
Other languages
English (en)
Inventor
Arlene E Mckeown
Thomas A Miller
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CO6190508A2 publication Critical patent/CO6190508A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un inhibidor de la histona desacetilasa (HDAC) y un compuesto metálico quelable, y un vehículo farmacéuticamente aceptable.2.- La composición farmacéutica de la Reivindicación 1, en donde el compuesto metálico quelable comprende hierro.3.- La composición farmacéutica de la Reivindicación 1, en donde el compuesto metálico quelable comprende zinc.4.- La composición farmacéutica de cualquiera de las Reivindicaciones 1 a 3, en donde el inhibidor de la HDAC es el ácido hidroxámico suberoilanilida (SAHA) o una sal o hidrato o solvato farmacéuticamente aceptable del mismo.5.- Una composición farmacéutica que comprende una cantidad terapéuticamente efectiva del complejo quelado Hierro-SAHA o un hidrato o solvato del mismo y un vehículo farmacéuticamente aceptable.6.- La composición farmacéutica de la Reivindicación 5, que comprende una cantidad terapéuticamente efectiva del complejo quelado Hierro-SAHA, en donde la relación estequiométrica de hierro a SAHA es de 1:3.7.- La composición farmacéutica de la Reivindicación 6, en donde el complejo quelado férrico SAHA es cristalino, y se caracteriza por un patrón de polvo de difracción de rayos X con radiación Ka del cobre, incluyendo picos característicos a 8.8, 14.5 y 1.8 grados 2?. 8.- La composición farmacéutica de la Reivindicación 6, en donde el complejo quelado férrico es cristalino, y se caracteriza por un patrón de difracción de polvo de rayos X con radiación Ka del cobre, incluyendo picos característicos a 8.8, 13.3, 14.5, 20.3, 21.8 y 24.6 grados 2?. 9.- La composición farmacéutica de la Reivindicación 6, en donde el complejo quelado férrico es cristalino, y se caracteriza por un patrón de difracción de rayos X con radiación Ka del cobre, incluyendo picos característicos a 8.8, 13.3, 14.5, 18.5, 20.3, 21.8, 24.6, 25.8 y 33.3 grados 2?.
CO09041802A 2006-09-28 2009-04-24 Composiciones farmaceuticas de inhibidores de la hdac y compuestos metalicos quelables y complejos quelados metalicos inhibidores de la hdac CO6190508A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84830006P 2006-09-28 2006-09-28

Publications (1)

Publication Number Publication Date
CO6190508A2 true CO6190508A2 (es) 2010-08-19

Family

ID=39230785

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09041802A CO6190508A2 (es) 2006-09-28 2009-04-24 Composiciones farmaceuticas de inhibidores de la hdac y compuestos metalicos quelables y complejos quelados metalicos inhibidores de la hdac

Country Status (14)

Country Link
US (2) US20090239946A1 (es)
EP (2) EP2079462A4 (es)
JP (1) JP2010504968A (es)
KR (1) KR20090064400A (es)
CN (1) CN101528212A (es)
AU (1) AU2007300532A1 (es)
BR (1) BRPI0717554A2 (es)
CA (1) CA2663569A1 (es)
CO (1) CO6190508A2 (es)
IL (1) IL197718A0 (es)
MX (1) MX2009003405A (es)
NO (1) NO20091664L (es)
RU (1) RU2009115860A (es)
WO (1) WO2008039421A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545968C (en) * 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
ES2370829T3 (es) * 2004-06-02 2011-12-23 Sandoz Ag Producto intermedio de meropenem en forma cristalina.
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2007053427A2 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
ES2442257T3 (es) * 2006-10-27 2014-02-10 Signal Pharmaceuticals Llc Formas sólidas que comprenden 4-[9-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-ciclohexan-1-ol, sus composiciones y sus usos
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AU2009305214B2 (en) 2008-10-15 2015-06-25 Generics [Uk] Limited Process for the preparation of vorinostat
WO2010062333A1 (en) * 2008-10-27 2010-06-03 Plus Chemicals Sa Polymorphs of vorinostat and vorinostat potassium salt and process for preparation thereof
CN102282126A (zh) * 2008-11-26 2011-12-14 基因里克斯(英国)有限公司 多晶型物
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2012030957A2 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TWI483721B (zh) 2013-09-05 2015-05-11 Profeat Biotechnology Co Ltd The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
EP3042652B1 (en) * 2013-09-05 2018-08-29 Profeat Biotechnology Co. Ltd. Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
KR102691700B1 (ko) * 2017-09-07 2024-08-02 아테넥스 에이치케이 이노베이티브 리미티드 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의 고체 형태
JP2022552642A (ja) * 2019-10-07 2022-12-19 ヴィラクタ サブシディアリー，インク． 副作用が軽減されたｈｄａｃ治療の調剤
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574822A (en) * 1976-03-23 1980-09-10 Lafon Labor Acetohydroxamic acid derivatives and pharmaceutical compositions thereof
US4315942A (en) * 1979-05-21 1982-02-16 New England Medical Center, Inc. Intravenously administrable iron supplement
US4335116A (en) * 1980-10-07 1982-06-15 University Patents, Inc. Mineral-containing therapeutic compositions
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4613616A (en) * 1984-07-20 1986-09-23 Research Corporation Polymeric iron chelators
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
CA2231251A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
EP1212357B1 (en) * 1999-09-08 2007-05-02 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
EA200601252A1 (ru) 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
CA2632078C (en) * 2002-03-04 2012-08-14 Sloan-Kettering Institute For Cancer Research Methods of inducing terminal differentiation
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
WO2005110399A2 (en) * 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
EP1784194A4 (en) * 2004-08-25 2010-12-29 Merck Sharp & Dohme HISTONE DEACETYLASE INHIBITORS
US7799937B2 (en) * 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions

Also Published As

Publication number Publication date
MX2009003405A (es) 2009-04-09
EP2079462A4 (en) 2009-12-02
EP2079462A2 (en) 2009-07-22
KR20090064400A (ko) 2009-06-18
CN101528212A (zh) 2009-09-09
EP2436382A1 (en) 2012-04-04
CA2663569A1 (en) 2008-04-03
RU2009115860A (ru) 2010-11-20
US20120142770A1 (en) 2012-06-07
IL197718A0 (en) 2009-12-24
WO2008039421A2 (en) 2008-04-03
AU2007300532A1 (en) 2008-04-03
US20090239946A1 (en) 2009-09-24
BRPI0717554A2 (pt) 2013-10-29
NO20091664L (no) 2009-04-27
WO2008039421A3 (en) 2008-07-24
JP2010504968A (ja) 2010-02-18

Similar Documents

Publication Publication Date Title
CO6190508A2 (es) Composiciones farmaceuticas de inhibidores de la hdac y compuestos metalicos quelables y complejos quelados metalicos inhibidores de la hdac
JP2010504968A5 (es)
MX2024008497A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
TW200740761A (en) Histone deacetylase inhibitors
WO2004082638A3 (en) Histone deacetylase inhibitors
GEP20105086B (en) Potassium salt of an hiv integrase inhibitor
RS52423B (en) THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT
TW200605881A (en) Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IκB kinase inhibitor
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
WO2006066133A3 (en) Histone deacetylase inhibitors
RS54754B1 (sr) Kristalni oblik argininske soli perindoprila, postupak njene proizvodnje i farmaceutske smeše koje je sadrže
UA95978C2 (ru) Ингибитор активации stat3/5
WO2007029035A3 (en) Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
TW200800944A (en) Benzamide compounds
WO2008109991A8 (en) Inhibitors of carnitine palmitoyltransferase and treating cancer
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
PH12020551488A1 (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
HRP20120700T1 (hr) SOLI SPOJEVA INHIBITORA HIV-a
WO2007024574A3 (en) Topical formulations of histone deacetylase inhibitors and methods of using the same
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
MX2009006638A (es) Agente para erradicar helicobacter pylori que tiene actividad inhibidora sobre la secrecion de acido gastrico.
MY147951A (en) Crystalline potassium salt of lipoxin a? analogs
GB2605894A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt
DE60331051D1 (de) Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten

Legal Events

Date Code Title Description
FA Application withdrawn